Belpointe Asset Management LLC Buys New Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Belpointe Asset Management LLC bought a new stake in shares of Anavex Life Sciences Corp. (NASDAQ:AVXLFree Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 10,000 shares of the biotechnology company’s stock, valued at approximately $93,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. BNP Paribas Financial Markets lifted its holdings in Anavex Life Sciences by 34.2% in the 4th quarter. BNP Paribas Financial Markets now owns 111,032 shares of the biotechnology company’s stock worth $1,034,000 after buying an additional 28,297 shares in the last quarter. Swiss National Bank lifted its holdings in Anavex Life Sciences by 2.5% in the 3rd quarter. Swiss National Bank now owns 177,700 shares of the biotechnology company’s stock worth $1,164,000 after buying an additional 4,400 shares in the last quarter. Premier Path Wealth Partners LLC acquired a new position in Anavex Life Sciences in the 4th quarter worth $116,000. Victory Capital Management Inc. acquired a new position in Anavex Life Sciences in the 4th quarter worth $100,000. Finally, SG Americas Securities LLC lifted its holdings in Anavex Life Sciences by 14.2% in the 4th quarter. SG Americas Securities LLC now owns 307,568 shares of the biotechnology company’s stock worth $2,863,000 after buying an additional 38,155 shares in the last quarter. Institutional investors and hedge funds own 31.55% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Anavex Life Sciences in a report on Friday, May 10th.

View Our Latest Stock Report on AVXL

Insider Transactions at Anavex Life Sciences

In other news, CEO Christopher U. Missling sold 73,380 shares of the stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $5.11, for a total transaction of $374,971.80. Following the transaction, the chief executive officer now owns 1,250,210 shares of the company’s stock, valued at $6,388,573.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 11.00% of the company’s stock.

Anavex Life Sciences Stock Performance

Shares of Anavex Life Sciences stock opened at $3.87 on Friday. Anavex Life Sciences Corp. has a 1 year low of $3.25 and a 1 year high of $10.45. The firm’s 50-day simple moving average is $4.08 and its 200-day simple moving average is $5.62. The firm has a market cap of $327.56 million, a PE ratio of -7.74 and a beta of 0.67.

Anavex Life Sciences (NASDAQ:AVXLGet Free Report) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). During the same quarter in the prior year, the firm posted ($0.17) EPS. On average, equities analysts predict that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current year.

About Anavex Life Sciences

(Free Report)

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.

Further Reading

Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXLFree Report).

Institutional Ownership by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.